The Social Security Administration (SSA) uses a screening tool called the Listing of Impairments to identify claimants who are so severely impaired that they cannot work at all and thus immediately qualify for benefits. In this report, the IOM makes several recommendations for improving SSA's capacity to determine disability benefits more quickly and efficiently using the Listings.
This book focuses on the coronary bioresorbable scaffold, a new interventional treatment for coronary artery disease, differentiated from a permanent metallic stent. The book provides an overview of the technology including non-clinical studies and clinical evidences in order to help clinicians understand the appropriate application of the technology and the optimal techniques of implantation. It covers the basics of bioresorbable scaffolds; bench test results; preclinical studies; clinical evidences; and tips and tricks of implantation.
In the past two decades a number of studies have shown that abnormalities in the function and structure of coronary microcirculation can be detected in several cardiovascular diseases. On the basis of the clinical setting in which it occurs, coronary microvascular dysfunction (CMD) can be classified into four types: CMD in the absence of any other cardiac disease; CMD in myocardial diseases; CMD in obstructive epicardial coronary artery disease; and iatrogenic CMD. In some instances CMD represents an epiphenomenon, whereas in others it represents an important marker of risk or may contribute to the pathogenesis of myocardial ischemia, thus becoming a possible therapeutic target. This book provides an update on coronary physiology and a systematic assessment of microvascular abnormalities in cardiovascular diseases, in the hope that it will assist clinicians in prevention, detection and management of CMD in their everyday activity.
Coronary Microvascular Obstruction in Acute Myocardial Infarction: From Mechanisms to Treatment provides a comprehensive understanding of the phenomenon of coronary microvascular obstruction (CMVO) that is the main limitation of reperfusion therapies in ST-elevation myocardial infarction. It provides in-depth coverage of the phenomenon of CMVO which heavily affects prognosis by increasing the risk of death and heart failure at follow-up. A first of its kind reference dedicated solely to this topic, it is appropriate for a wide audience, from researchers, to those who aid in the management, prevention and treatment of CMVO. - Provides in-depth coverage of coronary microvascular obstruction (CMVO), spanning research, management, prevention and treatment - Includes the most up-to-date information on CMVO as presented from top experts around the word - Provides access to a companion website with extra material, including tables, additional references and instructional videos - Gives extensive coverage on how to measure CMVO, including in-depth indexes that can be used to detect and quantify the phenomenon
Pathophysiology of Ischemia-Reperfusion Injury and Use of Fingolimod in Cardioprotection is a deep examination into the mechanisms of myocardial ischemiareperfusion injury and role of fingolimod as a cardioprotective agent through its antioxidant, anti-apoptotic and anti-inflammatory effects. Dr. Ahmed explore the physiology and pathophysiology of myocardial metabolism under normal and ischemic conditions and focused on pharmacological cardioprotection. They provide a concise, yet rigorous discussion of Ischemia-Reperfusion Injury, Myocardial Ischemia during Circulatory Arrest, Myocardial Reperfusion, Myocardial Protection related to Ischemia-Reperfusion Injury and Role of Fingolimod in Cardioprotection. Pathophysiology of Ischemia-Reperfusion Injury and Use of Fingolimod in Cardioprotection is ideal for researchers, cardiovascular scientists, and clinical pharmacologists to further work in this challenging area and apply this knowledge to clinical trials for cardioprotection.
New updated edition first published with Cambridge University Press. This new edition includes 29 chapters on topics as diverse as pathophysiology of atherosclerosis, vascular haemodynamics, haemostasis, thrombophilia and post-amputation pain syndromes.
This up-to-date textbook comprehensively reviews all aspects of cardiac CT and MRI and demonstrates the value of these techniques in clinical practice. A wide range of applications are considered, including imaging of atherosclerotic and non-atherosclerotic coronary artery disease, coronary revascularization, ischemic heart disease, non-ischemic cardiomyopathy, valvular heart disease, cardiac tumors, and pericardial disease. The numerous high-quality images illustrate how to interpret cardiac CT and MRI correctly for the purposes of diagnosis, treatment planning, and follow-up. Helpful summarizing sections in every chapter will facilitate rapid retrieval of information. This book will be of great value to radiologists and cardiologists seeking a reliable guide to the optimal use of cardiac CT and MRI in real clinical situations. An additional feature is the provision of QR codes allowing internet access to references, further figures, and motion pictures. The reader will be able to enjoy this book using a smartphone or tablet PC.
This sixth edition is enriched by over 300 figures, 150 tables and a video-companion collecting more than 100 cases also presented in the format of short movies and teaching cartoons. This extensively revised and enlarged edition of this long-seller documents the very significant advances made since the fifth (2009) edition and is entirely written by Eugenio Picano, a pioneer in the field sharing his lifetime experience with the help of an international panel of 50 contributors from 22 countries representing some of the best available knowledge and expertise in their respective field. In a societal and economic climate of increasing pressure for appropriate, justified and optimized imaging, stress echocardiography offers the great advantages of being radiation-free, relatively low cost, and with a staggering versatility: we can get more (information) with less (cost and risk). For a long time, the scope and application of stress echo remained focused on coronary artery disease. In the last ten years, it has exploded in its breadth and variety of applications. From a black-and-white, one-fits-all approach (wall motion by 2D-echo in the patient with known or suspected coronary artery disease) now we have moved on to a omnivorous, next-generation laboratory employing a variety of technologies (from M-Mode to 2D and pulsed, continuous, color and tissue Doppler, to lung ultrasound and real time 3D echo, 2D speckle tracking and myocardial contrast echo) on patients covering the entire spectrum of severity (from elite athletes to patients with end-stage heart failure) and ages (from children with congenital heart disease to the elderly with low-flow, low-gradient aortic stenosis).
Cardiovascular, respiratory, and related conditions cause more than 40 percent of all deaths globally, and their substantial burden is rising, particularly in low- and middle-income countries (LMICs). Their burden extends well beyond health effects to include significant economic and societal consequences. Most of these conditions are related, share risk factors, and have common control measures at the clinical, population, and policy levels. Lives can be extended and improved when these diseases are prevented, detected, and managed. This volume summarizes current knowledge and presents evidence-based interventions that are effective, cost-effective, and scalable in LMICs.
The chapters of this book represent contributions by plenary lecturers and invited symposium speakers of the Fourth Annual Meet ing of the American Section of the International Society for Heart Research, held on May 26-29, 1982 in New Orleans, Louisiana. The aim of the Organizing Committee was to present an up-to-date picture of our knowledge of myocardial injury which would be equally useful to basic scientists and clinicians. The papers of this volume are divided into two groups: a) those dealing primarily with techniques to study myocardial injury, and b) those that discuss the different types of myocardial lnJury. The grouping of the papers within each of these headings roughly corresponds to the symposia presented at the meeting. I wish to acknowledge the financial support of the National Institutes of Health. Without grant HL 29149, the program could not have been financed. Contributions from the following companies were also gratefully received: Ayerst Laboratories, Ciba-Geigy, Merck Sharp and Dome, Pfizer Laboratories Division, A.H. Robbin Co., Smith-Kline Corporation, U.S.V. Pharmaceutical Co., and The Upjohn Co. My thanks are due to the members of The Organizing Committee (Drs. Gregory J. Bagby, Gerald S. Berenson, Alastair H. Burns, Harvey I. Miller, Robert Roskoski, Jr., and Judy A. Spitzer) for their help and support, and to the Secretary of the Meeting, Ms. L. Beatrice Abene for her excellent assistance. John J. Spitzer, M.D.
